Lexicon Pharmaceuticals (LXRX) Gross Profit (2016 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Gross Profit data on file, last reported at $21.0 million in Q1 2026.

• Quarterly Gross Profit rose 1604.06% year-over-year to $21.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.3 million (up 126.46% YoY) and the FY2025 annual result came in at $49.5 million, up 62.58% from the prior year.
• Gross Profit advanced to $21.0 million in Q1 2026 per LXRX's latest filing, from $5.3 million in the prior quarter.
• Across five years, Gross Profit topped out at $28.8 million in Q2 2025 and bottomed at $155000.0 in Q3 2023.
• The 4-year median for Gross Profit is $1.6 million (2024), against an average of $8.5 million.
• The widest annual swing landed in 2024, when Gross Profit jumped 3665.23%; it then slumped 79.81% in 2025.
• Tracing LXRX's Gross Profit over 4 years: stood at $696000.0 in 2023, then jumped by 3665.23% to $26.2 million in 2024, then tumbled by 79.81% to $5.3 million in 2025, then surged by 296.71% to $21.0 million in 2026.
• Per Business Quant, the three latest LXRX Gross Profit figures stand at $21.0 million (Q1 2026), $5.3 million (Q4 2025), and $14.2 million (Q3 2025).

Peer Comparison